PG-30 Parkinson’s and the Promise of Cellular Dawn: After a Half-Century Wait, Are We on the Cusp of a Neural Renaissance? PG-42 Why Most Healthcare Contact Centers Fail — And What Strategists Are Doing Differently
PG-36 Stop Betting on Certainty: How to Pivot When the Market Doesn’t Bite
Biotechnologynowsitsattheforefrontofglobalproblem-solving.Asclimatestress,emergingpathogens, andagingpopulationsconverge,biotechleadersmustmovefasterandmoreresponsiblythanever
Thefielddemandsnotonlyscientificbrilliancebutentrepreneurialagility,ethicalstewardship,andthe abilitytotranslatemoleculardiscoveryintoscalable,equitablesolutions.In2025,impactwillbe measuredbyresults:livesimproved,ecosystemsrestored,andsystemsfortifiedagainstfutureshocks.
Thisedition,“TheMostInfluentialLeadersShapingtheBiotechIndustryin2025,”profilesthosewho embodythatmandate—scientiststurnedfounders,clinician-innovators,andexecutiveswhonavigatethe interfaceofresearch,regulation,andreal-worlddeployment.Theirleadershipisdefinedbycuriosity temperedwithprudence,byrisk-takingguidedbyevidence,andbyacommitmenttoensurethat breakthroughsservethemany,notthefew.
OurcoverstoryfeaturesSteveMcDaniel,FounderandCIOofReactiveSurfaces.Stevedidn’tendup mendingbones,buthewouldsoonbeworkingtomendtheveryfabricofourenvironment.Hiswork begannotwithagrandvision,butwithahumblecuriosityaboutsoilbacteria.Inthequietofhislab,he clonedagenecapableofproducinganenzymethatcouldmeticulouslybreakdownorganophosphorus pesticides—aneatbiochemicaltrickthat,foratime,wasonlyanelegantdiscovery.
AlongsideSteve,thisissuefeaturesJenniferKirk,Dr.LeenKawas,Dr.StanleyT.Crooke,andDr. KavithaP.Das—leaderswhoseinventionsandstrategicdirectionareacceleratingbiotech’spromise.As youturnthesepages,considerhowscience,ethics,andenterprisemustaligntocreatetechnologiesthat heal,protect,andsustainoursharedfutureforgenerationstocome.
HappyReading!
PARAG AHIRE PROJECT EDITOR
PUBLISHER
ARCHANA
EDITOR-IN-CHIEF
VIKRAM
MANAGING
PANKAJ
PROJECT
PARAG
PROJECT MANAGERS
JEREMIAH
RUSHIKESH LAHANE
RAJNISH KUMAR
VISUALIZER
MARK
GRAPHIC
HARSHADA
AAKASH
ROBERT
RESEARCH
JAMES
MARIA
SteveMcDanielneverintendedtospendhisdays
thinkingaboutpaint.Hewassupposedtobea doctor AsayoungmaninaPre-Medprogram, hesawhisfutureinthequiet,sterilehallwaysofa hospital;alifespentmendinghumanbodies.Hewas goodattheprerequisitesciences,particularly biochemistry,thatintricatedanceofmoleculesthat underpinslifeitself.Butthenhebecameahospital orderly,andtherealityofmedicine,theraw,visceral,and oftenheartbreakingproximitytosuffering,hithimwith anunexpectedforce.Herealizedhistemperamentwas bettersuitednotfortheimmediate,messyworkof healing,butforthepatient,methodicalsolitudeof research.Itwasapivotal,quietretreatfromthebedside totheworkbench,adecisionthatwould,inthemost unforeseenway,leadhimbacktoprotectinghuman healthonascalehecouldneverhaveimagined.
Stevedidn’tendupmendingbones,buthewouldsoon beworkingtomendtheveryfabricofourenvironment. Hisworkbegannotwithagrandvision,butwitha humblecuriosityaboutsoilbacteria.Inthequietofhis lab,hemanagedtocloneagene.Itwasaremarkable littlepieceofcodefromtheearth,capableofproducing anenzymethatcouldmeticulouslybreakdown organophosphoruspesticides.Itwasafascinating discovery,aneatbiochemicaltrick.Andforatime,that’s allitwas.
ThencameSeptember11,2001.Theworldchanged overnight.Suddenly,the “kissing cousins” ofthose pesticides,organophosphoruschemicalweaponslike VX,Sarin,andSoman,werenolongeradistantthreat butaterrifyinglyplausiblereality.ATVinterview,a casualquestionabouthisresearch,andafriendwitha businessmindwouldconspiretopullSteveMcDaniel andhisdirt-dwellinggeneintotheglobalwaronterror, andintheprocess,sethimonapathtocompletely reinventthesurfaceswetoucheveryday.
Thelogicwasdeceptivelysimple.Chemicalnerveagents arenotaninvisiblevapor;theyaretiny,insidious dropletsthataredesignedtosettleonsurfaces.They contaminateeverythingtheytouch:tanks,barracks, publicbuildings,computers,doorknobs.Thequestion posedtoStevewasstraightforward: Could his enzyme work against these weapons? Hisanswerwas conditional. “Only if that enzyme could be entrained in a coating system and placed on a surface,” hereasoned.
Itwasalightbulbmoment.Abusinessbrokerfriendsaw thepotentialimmediately.Ifheraisedthemoney,would Stevebewillingtostartacompanytofindoutifitcould work?Stevesaidyes.Andwiththat,in2002,Reactive SurfaceswasborninAustin,Texas.Themission wastotransformpassivesurfacesintoactive, self-decontaminatingshields.TheresultwasWMDtox,a coatingadditivethatwasnothingshortofrevolutionary. Testsconfirmeditwasover99%effectiveatneutralizing organophosphoruschemicalweapons.Theimplications werestaggering.AsSteveputsit,“a surface coated with WMDtox could be safely used as your dinner table just 24 hours after being exposed to a deadly nerve agent.”It wasn’tjustaclaim;inaSeptember2002decisionsheet, theNATOArmyArmamentsGroupvalidatedthe discovery,stating, “This technology could be of significant importance in dealing with sensitive equipment or vehicle/facility interior decontamination.” Theresearcherwhohadfoundmedicinetoo heartbreakingwasnowdevelopingtechnologytosave countlesslivesfromoneofhumanity’scruelest inventions.
TounderstandhowSteve’stechnologyworks,youfirst havetoreconsiderwhatacanofpaintreallyis.Weseeit asasimpleliquidcolor,butonamicroscopiclevel,it’sa complexandspaciousuniverse.Across-sectionofa polyurethanefilmrevealsalandscapeofpigment particlesandtitaniumdioxidecrystals,somemeasuring upto525cubicmicrometers.Atypicalbacterialcell,by comparison,isamerespeck,onlyacoupleof micrometersinsize.Evensmallerarebacterialspores. Whatthismeansisthatacoatofpaintisnotaseamless, impenetrablebarrier.Itisaporousscaffold,a microscopicmetropoliswithplentyofroomformicrobial tenantstomoveinandsetupshop.Apaintedwallcan becomeareservoirfordisease.
ThisiswherethegeniusofReactiveSurfaces’core innovationlies.TheenzymesandpeptidesSteveworks withareinfinitesimallysmall,theactiveenzymein WMDtoxislessthan0.01cubicmicrometers Theyare molecularmachinesfarsmallerthanthebacteriatheyare designedtofight.Byentrainingthesebioactivemolecules intoacoating,McDanieldiscoveredtheycouldretain theirfunction,effectivelytransformingtheentirepaint filmintoahostileenvironmentforcontaminants.Theyfit perfectlyintotheavailablespace,lurkingexactlywhere bacteriaandsporesreside,readytoact.
Thisprincipleopenedupaworldofpossibilities beyondchemicaldefense.Apivotalopportunity arosewhenSteve,whoisalsoanintellectual propertyattorney,wasrepresentingabiotech startup.Theclienthaddevelopedalibraryof53 millionsyntheticantimicrobialpeptides(AMPs) intendedtotreatrespiratoryinfectionsinAIDS patients,buttheprohibitivecostsofbringinga newpharmaceuticaltomarkethadshuttered theirefforts.Insettlingtheiraffairs,Stevemade ashrewdoffer:hewouldexchangehislegalfees forthepatentrightstotheirentirepeptide library.Hehadahunchhecouldentrainthese AMPsintoacoating,justashehadwithhis enzyme.Hishunchwascorrect.Theresultwas ™ProteCoat ,anon-toxic,non-leaching antimicrobialadditivethatworksforaslongas thecoatingitselfisintact.
Itwasasafer,moredurablealternativetoexistingtechnologieslike MicroBan,whichleachestoxinsandhasbeendeemedecotoxicin theEU.Thisinnovationalsoaddressedadeeperconcernwithin healthcareitself.In2015,forexample,KaiserPermanentechoseto banantimicrobialcoatingsfromitshospitals,notoutof indifference,butinalignmentwiththemedicalethicof“first,dono harm”(primumnonnocere).
Traditionalwaterbornecoatingsrelyontoxicbiocidestoprevent spoilageinthecan,andonceapplied,thosetoxinscanleachintothe environment,puttingvulnerablepatientsatrisk.ReactiveSurfaces tookadifferentpath.Bycreatingandpatentingin-canpreservatives madefromnaturallyoccurring,safeingredients,thecompany eliminatedtheneedfortoxicbiocides.Evenmoresignificantly, thosesamesafepreservativescontinuetoperformoncethepaintis applied,providinglastingantimicrobialprotectionwithout compromisingpatientsafety.Indoingso,ReactiveSurfacesturned abarrierintoasafeguard,aligningsciencewithmedicalethics.
Theproblemwithconventionalsurfacecleaningisthat it’satemporaryfix.Disinfectantslikebleachwork,but theymustbereappliedeverytimeasurfaceis contaminated.It’saconstant,Sisypheanbattle.Steve’s enzyme-basedapproachoffersamoreelegantand resilientsolution.Oncethecoreprinciplewas established,theapplicationsbegantomultiply.Ifan enzymecouldbreakdownachemicalweapon,what elsecoulditdeconstruct?
™
TheanswerledtoinnovationslikeDeGreez .By entraininglipolyticenzymes,whichbreakdownfats, oils,andgreases,intoacoating,thesurfaceessentially createsamicroscopiclayerofsoap.Fingerprints, greasesmudges,andoilyfilmsarecontinuously brokendown,makingthesurfaceeasiertoclean.
It’sthebasisforanti-fingerprintcoatingsoncomputersandselfcleaningtechnologyforeverythingfromkitchencounterstosewer pipes.Anotherapplicationtacklesthegrowingcrisisofantibiotic resistance.ByentrainingenzymesthatbreakdownDNAand RNA,ReactiveSurfacesdevelopedcoatingsthatdestroystray geneticmaterialintheenvironment,preventingmicrobesfrom incorporatingantibioticresistancegenesintotheirgenomes.
Theserepresentafundamentalshiftinhowweinteractwithour builtenvironment.Thesurfaceisnolongerapassivevictimof contaminationbutanactiveparticipantinitsownhygiene.
Leadingahigh-stakesbiotechfirmrequiresmorethanjust scientificbrilliance;itdemandsacultureoffierceprotectionand collaborativecreativity. “As a CIO, you must not just innovate, you must protect these innovations,” Stevestates.
INNOVATION IS A TWO-PART MISSION: YOU MUST NOT ONLY CREATE, YOU MUST FIERCELY PROTECT THAT CREATION. SOMETIMES THAT MEANS TAKING ON A GOLIATH, NOT JUST FOR THE ROYALTY, BUT FOR THE PRINCIPLE THAT GOOD SCIENCE DESERVES TO WIN.
Thisphilosophywasputtotheultimatetestina David-and-Goliathbattlewithoneoftheworld’s leadingcarmanufacturers.ReactiveSurfaceshad pioneeredandpatentedanenzymaticsolutionforoily fingerprints.Theautogiantsoughtandwrongly obtainedpatentsforasimilartechnologyafterthem.
Invalidatingapatentheldbyaglobalcorporationisa monumentalandexpensiveundertaking.Stevehadto findhighlyskilledlitigatorswillingtotakeonthe caseinexchangeforashareoffutureroyalties.He succeeded.Theattorneysinvalidatedthewrongfully obtainedpatents,securingavictorythatwasasmuch aboutprincipleasitwasaboutprofit.It’satestament tohisdualidentityasbothinnovatorandlegal strategist.
Thisdriveisfueledbyacultureofsharedcreation. Stevedoesn’tseehimselfasthesoleinnovatorbutas afacilitator.Heengenderscreativitybybringingin leadingscientistsfrompowerhouseinstitutionslike theUniversityofSouthernMississippi,North America’spremierpaintandpolymerdepartment,the UniversityofTexas,andColoradoStateUniversity. “To be creative, lead with intuition and inspiration, and not merely intellect,” Steveadvises.
Thisapproachhasyieldedsignificantrecognition.In 2008,ReactiveSurfacesandtheiruniversitypartners receivedthefirst-everAmericanCoatingsAward,an honorgiventotechnologydeemedlikelytochange theindustryforthenext50years.Morerecently,the companywonthe 2021 Waterbourne Coatings Siltech Best Paper awardforaclimatechangetechnology, anditsPresident,BethMcDaniel,Steve’swifeand businesspartner,wasnamedaThoughtLeaderby Coatings World magazinein2024.
Today,themissionofReactiveSurfacescontinuesto expand.Theyhavebuiltanimpressivetoolboxof materialsthatcanserveasafirstlineofdefense againstmicrobialcontaminationandantibiotic resistance.Thenextfrontierismigratingthese laboratorysuccessesintoclinicaltrialstoprovetheir efficacyinreal-worldhospitalsettings.
Buttheambitiondoesn’tstopthere.Thesame innovativethinkingthatturnedawallintoa self-cleaningsurfaceisnowbeingappliedtooneof themostexistentialthreatsofourtime:climate change.
ReactiveSurfacesinvented‘CarbonCapture Surfaces,’atechnologydesignedforthedirect removalofexcesscarbondioxidefromthe atmosphere.ThecompanywasnamedaTop100 Finalistinthe$100MillionXPRIZEfortheBest CarbonDioxideRemovalTechnology.Although thatcompetitionhassinceconcluded,the recognitionunderscoredthepotentialoftheir approach.It’satechnologyaimedataddressingthe rootcauseofhealthcrisesfromrespiratorydisease tothespreadofinfectiousillnesses.
ForSteve,theintensepressureofthisworkis counterbalancedbyalifeofmindfulpursuits.A lifelonginterestinmeditationprovidesacalm center.Fly-fishingandgardeningoffera connectiontothenaturalworldthatfirstinspired him.Buttheultimatekeytohiswork-lifebalance, hesays,ishavinghiswife,Beth,ashis entrepreneurial,business,andspousalpartner Together,theynavigatethefinancialandtime constraintsoftheinnovationbusiness.
Fromasinglegenefoundindirt,SteveMcDaniel hasbuiltauniverseoftechnologiesthatare makingtheworldsafer,cleaner,andmoreresilient. Themanwhoonceshiedawayfromtheheartbreak ofmedicinehasfoundawaytohealtheworld,one surfaceatatime.
Effectiveleadershipandimpactful
researchintoday’scomplex healthcarelandscapeoften involvesaddressingtheintersectionsof clinicalcare,evidence-basedresearch,access tocareprinciples,andeffectivemanagement. Dr.KavithaDasoperatespreciselyatthis convergence.Sheleveragesherdiverse backgroundindentistry, medical-dental integration,publichealth,andresearch experiencetodevelopandimplement initiativesaimedatimprovinghealth outcomesandaccesstocare.Herwork focusesparticularlyonaddressingsystemic fragmentationinhealthcareandpromoting preventiveandearlydetectionstrategies.
Dr.Das’scommitmenttohealthpromotion anddiseasepreventionbeganearlyinher careerasanewlygraduateddentistin Bangalore,India.Whileworkingalongside anoralandmaxillofacialsurgeon,she witnessedthedevastatingeffectsofdelayed healthcare.“Wesawnumerouspatients presentingwithearly-stageoralcancers,” sherecalls.Thetroublingrealitywasthat manydidnotreturnforfollow-upcare Whentheyreturnedmonthslater,their cancershadsignificantlyprogressed,often requiringextensivesurgeryand chemotherapy.
“This experience deeply impacted me,” Dr Dasreflects.“Ithighlightedthecritical roleofhealtheducation,publicawareness, androutinewellnessscreeningsin improvingpatientoutcomes.”Thedesire “tomakeabroaderimpact”setheronanew trajectory.
ThisrealizationmotivatedDr.Dastopursue aMasterofPublicHealth(MPH)inSocial andBehavioralSciencesandInternational HealthfromBostonUniversity.This programprovidedherwithaframeworkfor understandinghealthchallengesata populationlevel.
Afterward,shereturnedforintensive clinicaltraining,completingasecond residencyandearningaMaster’sdegree inProsthodonticsfromColumbia UniversityCollegeofDentalMedicine. Asshemasteredcomplexdental rehabilitation,sheencountereda recurringtheme:thecriticalimportance ofpatientunderstanding.
“Irealizedonceagainhowessential patienteducationisforensuringthe long-termsuccessandmaintenance ofimplant-supportedtreatments.” Sheclearlyrecognizedthesignificant savingsinbothcostandsufferingthat couldbeachievedthroughearlier intervention.
“Since completing my MPH, my work has consistently taken an interdisciplinary approach,” Dr.Das notes.Herpathincluded:
● Programmanagementandresearch inHIV/AIDSatYaleUniversity SchoolofPublicHealth
● Theresearchfocusedonolderadult healthatColumbiaUniversity.
● Aneight-yeartenureasaSenior ScientistinCardiologyatthe IcahnSchoolofMedicineat MountSinai,whereshe investigatedthecruciallinks betweencardiovasculardisease, diabetes,andoral-systemichealth.
Duringtheseyears,akeyobservation emerged.Dr.Dasnoted,“Iobserved thatdentalandmedicalprofessionals oftenworkinsilos,resultingin fragmentedcarewherethepatient ultimatelysuffers.”Itwasacallto action. “This realization led me to shift my focus toward translating research into practical, community-based solutions that improve care access to care across all populations.”
Dr.Dasnowchannelsherexpertiseintokey leadershiprolesinresearchandtranslational science.Shefocusesonenhancingeldercare throughherrolesasaDirectorforResearch andManagementinmultiplesettingslike adultdaycarecentersandnon-profitsectors byintegratingvarioushealthservices, implementingandevaluatingresearch findings,andtailoringprogramstoimprove thequalityoflifeforseniors.
Dr.KavithaDashasalsobeenleadinghealth policyandadvocacyeffortsforover10 years.ShewastheCo-ChairforHealth PolicyandAdvocacyforthePublicHealth AssociationofNYC,andnowservesasthe
ChairforthePolicyandAdvocacy CommitteeforNYCattheNewYork StatePublicHealthAssociation.Inthis role,sheworkswithhealthcareand publichealthprofessionalstoeducate thepublicandlegislatorsonhealth issuesthatareharmfultothepopulation.
Dr.Dastakesonahands-onrole, describingherselfasa“jackofall trades”involvedingrantwriting, research,proactivepopulationoutreach, andfosteringcollaborationsacross healthcare,industry,andtechnology sectors.Sheaimstoalleviatetheburden ofdiseasethroughinnovation, prevention,earlydetection,precision medicineandhealtheducation.
Acrosshervariousroles,Dr.Dasemploysaconsistentset ofcorestrategiesgroundedinherdiversebackground:
● InterdisciplinaryCollaboration:Dr.Das emphasizes, “Collaboration is key,” highlightingthe importanceofengagingwithawiderangeof stakeholders,includingindustryleaders,faith-based leaders,healthcareprofessionals,academics, communityleaders,legislatorsandbiotechinnovators. Herabilitytonavigatethesediverseinteractionsis partlyattributedtoherexperiencelivingin multiculturalenvironmentssuchasBangaloreand NewYorkCity.Herapproachfocusesonfostering trustandrapport,maintaininganopen-doorpolicyfor stakeholders,andbuildingcomplementaryteamsand alliances.
● FocusonPrevention&EarlyDetection:Drawing directlyfromherearlyclinicalexperiences,Dr.Das activelypartnerswithorganizationsprioritizing preventionandearlyinterventionfornoncommunicablediseaseslikediabetesandheartdisease. Shechampionstheuseofdigitalhealthtoolsthatserve dualroles:educatingindividualsandempowering them “to take responsibility for their own health without judgment.”
Anotableexampleofherproactiveapproachwas pioneeringtheuseofhighaccuracypoint-of-care (POC)testinginNewYorkCityschoolsduringthe COVID-19pandemictominimizevirusspreadand facilitateareturntoin-personlearning.Shecontinues toexplorepartnershipsinvolvingnewPOCtesting devicesandmobileapplicationsforearlydetectionof conditionslikecervicalcancer,metabolicdiseases, irondeficiencyanemia,andbeta-cellthalassemia.
● TechnologyIntegration:Centraltoheruseofdigital healthtoolsandPOCtestingisastrategyofleveraging technologytoenhanceaccessandimprovehealth outcomes.Dr.Dasactivelyseekspartnershipswith healthtechinnovatorstoincorporatenovelapproaches intocommunity-basedandcorporatehealthprograms.
● PolicyandAdvocacy:Knowledgeispowereducatingpeopleacrossdiversegroupsisvitaltothe uptakeanduseofevidence-basedhealthresearch outcomesanduseofnewhealthtechnologytoolsto minimizethelongtermimpactofchronicdiseases.
Leadingchangealwayscomeswithchallenges.Dr.Das highlightsthedifficultiesinchangingestablished mindsetswithinthehealthcaresystem,whichshenotes isprimarilyfocusedonpatientcare.Sheexplainsthat persuadingstakeholderstoadoptamorecomprehensive approach—onethatincludespreventionandearly detection—isoftencomplicatedbytheiremphasison short-termgoals.
Theseimmediateneedsfrequentlyoverlookthelongtermbenefitsofprevention,whichhasbeenshownto savemoneyandreducesuffering.Asaresult,Dr.Das feelstheneedtobecreativeinherstrategies,workingto bridgethegapbetweenstakeholders’immediate requirementsandtheirlong-termobjectives.
Dr.Dasmaintainsenergyforherdemandingroles throughactivitiesoutsideherdirectprofessional commitments.SheispartofagroupinNYCwhoare knowninNewYorkCityfororganizing “entertaining events in the fundraising space,” citingexampleslike salsadancingnights,chocolatetastings,fashionshows, and5krunsaspersonalstressrelievers.
Moreover,shevaluestimespentunwindingwithfriends andfamily,acknowledgingtheircrucialsupport.Her coreleadershipphilosophyappearsstraightforwardyet powerful:“Lovewhatyoudo,anddoitwell-people aredrawntogenuinepassionandpurpose.”This principleseemstofuelherdedicationacrossherdiverse responsibilities.
Lookingforward,Dr.Dasremainsfocusedoncreating scalableandimpactfulsolutions.Ifgrantedunlimited resources,herfocusturnstofundamentaldeterminants. “Poverty is directly linked to poor health,” sheasserts. Herprioritywouldbe“povertyeradication,while simultaneouslyfocusingonskillbuildingand nutritioneducationusingeasilyaccessibledigital toolsandculturallytailoredmessages,sothatthe individualenjoyslearning!”
Theemphasisonengagementiscrucial:“Making learningenjoyable...aresurefirewaystoencourage themtocontinuetheirjourneytowardbetterhealth.”
Forfiftylongyears,thetherapeuticarsenalagainst Parkinson’sdiseasehasbeendominatedbyasingle stalwart:levodopa Thisdrug,achemicalprecursor thatthebrainfaithfullyconvertsintodopamine,hasoffered solacetomillions,quietingthetremorsandeasingthecruel stiffnessthatprogressivelystealsmovementandgrace.Yet, levodopaisatreatment,notacure.Itreplenishesa dwindlingneurochemicalsupplybutdoeslittletohaltthe inexorablemarchoftheunderlyingneurodegeneration-the slow,silentdeathofdopamine-producingneurons
Butnow,adistinctandpalpableexcitementisrippling throughtheneurosciencecommunity.Twometiculously conductedstudies,gracingthepagesoftheesteemed journal Nature thisweek,havekindledanewflameofhope. Theywhisperofafuturewherewemightnotjustmanage Parkinson’s,butperhaps,begintomendtheveryfabricof theafflictedbrainusingtheextraordinarypotentialofstem cells
TheCellularSolution:ReplacingtheLostFactories
Parkinson’s,thesecondmostcommonneurodegenerative disorder,fundamentallyarisesfromthislossofspecific nervecells.Thesecellsarethebrain’sdopaminefactories, andtheirabsencedisruptsthedelicatesymphonyof movement.Thenewresearchdoesn’tjustaimtosupplement dopamine;itaimsto replace thelostfactoriesthemselves.
TheKyotoProtocol:PioneeringiPSCs
Thefirstoftheselandmarktrials,emergingfromKyoto UniversityHospitalinJapan–aplacewithastoriedhistory instemcellscience–exploredtheuseof“induced pluripotentstemcells”(iPSCs).Theseare,inessence,adult humancellsingeniouslyreprogrammedbacktoa‘blank slate’state,fromwhichtheycanbecoaxedtodifferentiate intovirtuallyanycelltype.Inthisinstance,theywereguided tobecomedopamine-producingneurons Sevenpatients receivedthesebespokecellstransplantedintotheirbrains.
Theprimaryvigil,aswithanypioneeringtherapy,wasfor safety The Nature reportisreassuring:noserious adverseeventswereattributedtothecells,andcrucially, nosignsofuncontrolled,tumor-likegrowth–ashadow thathaslongloomedoverstemcelltransplantation.While 73mildtomoderateeventswerenoted,thefundamental safetyprofilewasencouraging.
Butbeyondsafety,werethereglimmersofefficacy?Two yearspost-transplant,thesixevaluableparticipants showedtangibleimprovementsonstandardclinicalscales measuringParkinson’smotorsymptoms.Their“on”time (whenmedicationcontrolssymptoms)improvedbyan averageof36%,andthedebilitating“off”timereduced by20%.Furthermore,PETscans,usingaradioactive tracertofollowlevodopa’spathlikeamolecularbeacon, indicatedasubstantialincreaseindopamine-producing cellactivity Thenewcellulargraftsappearedtobe takingrootandfunctioning.
TransatlanticEfforts:EmbryonicStemCellsShow Promise
Concurrently,asecondtrial,conductedacrosssitesinthe U.S.andCanada,employedadifferenttypeofstemcell derivedfromhumanembryos.Thisstudy,involving 12participantsandfollowingthemforayear,testeda therapycalledbemdaneprocel,developedbyBayer’s subsidiaryBlueRockTherapeutics.Thesafetyfindings mirroredtheJapanesestudy:nodeathsorserious adverseeventslinkedtothecells,andnotumor-like growth.(Oneparticipantwashospitalizedwith COVID-19,anotherexperiencedaseizureattributedto thesurgicalprocedureitself,highlightingtheinherent risksofanybrainintervention).Encouragingly,thistrial alsoreportedimprovementsin“off”scoresandpositive signalsfromtheradioactivelevodopatests.BlueRock Therapeutics,whichhadsharedsomeofthisdatabackin August2023,isnowpoisedtoembarkonalargerPhase 3trialbeforetheendofJunethisyear(2025)
Thisdreamofcellularreplacementfor Parkinson’sisnotbornofyesterday Asfar backas1989,OlleLindvallandhisteam undertookthefirstsuchtransplantations.While thatlandmarkeffortdidn’tyielddramatic therapeuticbreakthroughs,itprovided tantalizingsignalsthatspurreddecadesof furtherresearch.Onesignificantethicalhurdle fromthaterawastherelianceonfetaltissue. Theinterveningyearshaveseenprofound advancements,particularlythe2006Kyoto UniversityinnovationofiPSCs,offeringless controversialandmorescalablesourcesfor thesetherapeuticcells.Indeed,amilestonewas reachedin2020whenaParkinson’spatient’s own skincellsweretransformedand implanted.
AsofDecemberlastyear(2024),thegloballandscape revealed115clinicaltrialsinvestigating83different pluripotentstemcell-derivedproducts,withthose targetingParkinson’sdiseaseamongthemostadvanced. CompanieslikeAspenNeurosciencearealsoinearly-stage humantestingwiththerapiesderivedfrompatients’own cells.
HideyukiOkano,adistinguishedstem-cell scientistfromKeioUniversityinTokyo,inan accompanying Nature editorial,rightly tempersexcitementwithcaution,emphasizing thatmoreresearchisvitaltodefinitivelyprove efficacy Yet,hecallstheresults “encouraging,”primarilybecausethey robustlysuggestthattransplantingdonorcells intothebrainsofParkinson’spatientsislikely safe.Thatboththeseindependenttrials “provedtobesafe,andhintedatpossible efficacy,isanimportantsteptowardsthe establishmentofthiscelltherapyfor Parkinson’sdiseaseinwidersociety,”hewrote.
Wearewitnessingnotasuddenrevolution,butthe culminationofdecadesofpainstakingwork,of understandingtheintricatebiologyofstemcellsandthe cruelpathologyofParkinson’s.These Nature studiesdonot yetheraldacure.Buttheyrepresentasignificant,deeply hopefulstrideforward.Theysuggestthatthelong-held aspirationofrepairingtheParkinson’sbrainatacellular levelismovingfromtherealmoftheoreticalpossibilityinto tangibleclinicalreality.Thepathaheadwillrequirelarger trials,longerfollow-up,andcontinuedvigilance.Butforthe millionslivingundertheshadowofParkinson’s,thisnew researchkindlesapowerful,andscientificallygrounded, senseofanewcellulardawn.
Dr.LeenKawasknowswhatittakestodisruptan
industryandshehasdoneitwithbiotechinways fewcouldimagine.Frompioneeringdrug developmentsforAlzheimer’stofoundingPropelBio Partners,alifescienceinvestmentfirm,she’sbreaking groundnotjustintreatments,butinhowtheentiresector thinksaboutinvestment,growth,andinclusivity
Herstoryisnotoneofluckoreasysuccess.Every milestoneishard-won,groundedinrelentlessinnovation andaneyeforopportunitythatfewotherscansee.For Leen,themissionhasalwaysbeenclear:developsolutions thathavereal,lastingimpactsonhumanhealth.Thismeans discoveringandinvestingintechnologiesthatothersmight overlookbutthatsheknowscanchangelives.
TheRiseofaBiotechPioneer
Leen’sjourneyinbiotechdidn’tstartwithacushyroleor generousfunding.Shebuiltherexpertiseandcareerfrom thegroundup.In2014,sheco-foundedAthiraPharmaand broughtingroundbreakingideasaroundneurological diseases.Inbiotech,thepressuretodeliverisn’tjuston profitsbutonproducingtangible,life-savingresults.Leen’s relentlessdrivehelpedherraiseover$400million, culminatinginoneoftheindustry’smostnotableIPOs,and shediditwhilebreakingstereotypesleftandright.
What’sthesecret?Leenfocusesonthebigpicturewhile zeroinginoneverydetail.Shedoesn’tjustwantnew therapiesinthemarket—shewantstoreshapehowpatients receivethem,howresearchersthinkaboutthem,andhow investorssupportthem.It’savisionthatgoesbeyond products;it’saboutshapingthefutureofhealthcare,and she’sjustgettingstarted.
PropelBioPartners:RethinkingBiotechInvestments
NowatPropelBioPartners,LeenleadsasManaging GeneralPartner,targetingaveryspecificchallenge: findingthebiotechfirmswithpotentialfortransformational changeandgivingthemthesupporttheyneedtogetthere. PropelBioPartnersisnotjustanotherinvestmentfirm;it’s
aplatformbuiltaroundcollaborationandsupportforhighpotential,early-stagelifesciencescompanies.
“We’reinvestinginpeopleandideasthathavethe potentialtofundamentallyimprovelives,”shesays.With afocusonbothsmall-cappublicandprivatecompanies, PropelBioistakingaholisticapproach.ForLeen,each investmentdecisiongoesbeyondfinance;itinvolves evaluatingthetechnology,theteam,andtheimpactthey couldhaveonthefutureofhealthcare.Hereyeforfinding andnurturingpotentialdoesn’tjustcomefromyearsof experiencebutfromadeep-rootedbeliefinwhatbiotech canachievewhenfueledbytherightvisionandvalues.
ChallengesandTriumphsofBeingaFemaleLeaderin Biotech
Inasectorwhereinnovationandprogressarekey,Leen hasseenthatforwomen,thepathisoftenmore challenging.She’soneofjust22femalefoundersand CEOstotakeacompanypublicinbiotechasof2021—a staggeringstatisticthatunderscorestherarityofher accomplishment.Despitetheseodds,Leendidn’tjust navigatethebiotechlandscape;shereshapeditforherself andthosewhocameafterher.
Butit’snotjustaboutbreakingrecords.Leenknowsthat leadingacompanyinbiotechmeansconfrontingaunique setofchallenges.WhensheledAthirathroughitsIPO,it markedthefirsttimeinover20yearsthatawomanhad guidedabiotechcompanytopublicstatusinWashington State.Therecognition,whilesignificant,onlymadeher moreawareoftheworklefttodoforwomeninscience andleadership.
“It’sharderasawoman;there’snodoubtaboutit,”she says.“ButIdidn’tletthatdefinemeorlimitmygoals.” ForLeen,thefocusisclear:buildcompaniesthatcan standthetestoftime,andcreatepathwaysforother womentodothesame.It’sanapproachthathasseenher gainnotonlyindustryaccoladesbutalsothetrustand respectofanewgenerationoffemalescientistsand entrepreneurs.
TounderstandLeen’sleadership,looknofurtherthanher workatAthira.Asco-founder,shedidn’tjustoversee operations;shewasdeeplyinvolvedinscientificresearch anddrugdevelopment.Athira’sleadcandidate,ATH-1017, aimedattreatingAlzheimer’s,representsoneofhermajor contributionstothefield.Bringingthistoliferequirednot onlyscientificacumenbutalsothetenacitytosecure fundingandnavigatethecomplexitiesofclinicaltrials, regulatorypathways,andpublicinterest.
Raising$400millionandsuccessfullytakingAthirapublic, Leenputherself—andthecompany—onthemap.Shesays, “Thehardworkwasn’tjustingettingtotheIPO;itwasin ensuringthatwhatwewerebuildinghadrealsubstance, realpotentialtochangelives.”Thatclarityofpurposegave hertheedgeneededtoseethecompanythroughitsmost challengingtimes,includingtheimmensepressurethat comeswithapubliclisting.
Today,atPropelBioPartners,Leenleverageseverything shelearnedfromheryearsatAthira.She’snotinterestedin beingapassiveinvestor;she'sactivelyinvolvedinguiding portfoliocompanies,offeringstrategicinputoneverything fromregulatorypathwaystoproductdevelopment.Propel Bioisn’tjustaboutinjectingmoney—it’saboutbeingpart ofthejourney,ensuringthatthecompaniestheysupport havetheresourcesandguidancetheyneedtosucceed.
PropelBioPartnersoperatesonasimplebutpowerful premise:realtransformationinhealthcaretakesmorethan justcapital;ittakesacommunityofexpertsandadvisors. Byprovidingthisnetwork,Leenandherteamare rethinkingwhatitmeanstobealifesciencesinvestor “Everycompanyweworkwithispartofalargermissionto createbetter,moreeffectivehealthcaresolutions,”shesays. ForLeen,it’snotenoughtoseeapromisingtechnology; sheneedstoknowithasthepotentialtobenefitpatientsand thatit'sbeingledbypeoplewhosharethatcommitment.
Beyondtheboardroomandlab,Leen’svoiceisoneof advocacy.Sheactivelysupportsgenderequity,butnotina performativeway.AtPropelBio,herfocusondiversityin portfoliocompanieshappenednaturally,withamajorityof herfirm’sinvestmentslandinginwomen-ledventures.
ForLeen,itwasn’taquotatobefilledbutratherareflectionof herbeliefthatgreatideascancomefromanyoneandshouldbe supportedwherevertheyarise.
“Sometimes,it’saboutjustshowingupandprovingthatwomen canleadatthehighestlevels,”shesays.Leen’sstraightforward approachresonatesacrosstheindustry,inspiringotherwomento seetheirownpotentialinbiotechandentrepreneurship.She recognizesthatbeingoneofthefewwomentotakeabiotech companypublicismeaningful,butshe’smorefocusedon ensuringthatothersfollowherpath—andperhapsevensurpassit.
AsLeenlookstothefuture,hergoalsforPropelBioPartnersare ambitious.She’snotcontenttosimplygrowthefund;shewants tobuildaninvestmentmodelthatothersintheindustrycanlook to.Thismeansactivelyengagingwithcompaniesandsettinga newstandardforwhatinvestorscan—andshould—bringtothe tablebeyondfunding.Hereyesareonthehorizon,thinkingabout theevolutionofpatient-centrichealthcareandhowPropelBiocan playaroleinmakingitareality
Dr.Kawasisquicktopointoutthatherroleisfarfrom conventional;sheseesherselfaspartofanewbreedofinvestors whoaredeeplyinvolvedinthecompaniestheysupport.“We investmethodicallyandsupportthoughtfully,”sheexplains.For her,successisn’tjustmeasuredinreturnsbutinreal-world impact,inseeingcompaniesshebackedachievebreakthroughs thatreshapethehealthcarelandscape.
Leen’sjourneyhasnotbeenaneasyone,andthat’sexactlywhy it'ssoinspiring.Fromgroundbreakingscientificworktobreaking downgenderbarriersinbiotech,herpathhasbeenanythingbut typical.She’ssettinganexamplenotjustforfemaleleaders,but foranyonewhobelievesinthepowerofinnovationtomakea difference.
Inanindustrythat’sslowtochange,LeenKawasisacatalyst. HerworkatPropelBioPartnersisn’tjustaboutreturnsor prestige—it’saboutcreatingsomethingbiggerthanherself.She’s avisionarywho’srewritingtherulebookonwhatitmeanstolead, invest,andinnovateinbiotech.
ForDr.LeenKawas,themissionisclear:revolutionize healthcare,onebreakthroughatatime.Andasshedoes,she’s showinganentireindustrywhatitlooksliketoleadwithpurpose andpassion.
Inpharmaandbiotech,weoftenrunthesameriskas early-stageentrepreneurs:wefallinlovewithanidea beforewetestwhetherthemarketlovesitback.
Thismistakehappensateverylevel.Fromstart-upfounders pushinga“game-changing”therapywithoutenoughclinical traction,tomultinationalexecutivesgreenlightingaproduct linebasedoninternalexcitementratherthanexternaldemand.
I’vemadethesamemistakemyself.AndwhenIdid,Ilearned oneofthemostprofitablelessonsofmycareer:
Beingtooweddedtoaspecificoutcomeblindsyoutothe betterpathrightinfrontofyou.
Afewyearsago,IhadwhatIthoughtwasaperfectplan.
professionalofferIbelievedwasirresistible.
Ihadaresourcesittingidle.Ihadanetworkthatcouldbenefit fromit.Ihadthemotivationtomakeithappen.
IputtheideainfrontofsevenpeopleIconsideredanidealfit. Thekindofpeoplewhoregularlyexpressedinterestinexactly thistypeofopportunity.
Iexpectedatleastacoupleofquick“yes”replies.Bags packed.Commitmentsmade.
· “That’sanamazingoffer.”
· “Wow,I’dloveto…butnotrightnow.”
· “I’llthinkaboutit.”
Andthen—silence.
Nosign-ups.Noaction.Noconversion.
Icoachleadersallthetimeonthefundamentalsofa compellingoffer:
· Understandtheproblemyousolve—inprecise,marketrelevantterms.
· Showexactlywhyyoursolutionworks,withevidence andproof.
· Connecttotheurgencythatalreadyexistsinyour audience’smind.
· Maketheoffersoalignedandsoclearthatrejection feelsirrational.
· Putitinfrontofenoughofthe right people—notjust peoplewhomight“like”theconcept.
Ididnoneofthesethings.
ImadeanofferbasedonwhatIwantedforthem—noton whattheywereactivelyseeking.
Iremovedallfrictionbutalsoremovedallcommitment.
Andwithouturgency,cost,ordirectalignmentwiththeir priorities,theydidwhathumansusuallydowithrisk-free, low-commitmentoffers:
Ifyou’vebeeninbiotechorpharmaformorethana quarter,you’veseenthispattern.
highinternalenthusiasm…onlytowatchthemstall.
Why?
Becausetheinternallogic(“Thisisbrilliant!Itwillhelp themsomuch!”)doesn'talwaysmatchthemarketreality (“We’renotready,we’renotconvinced,wehavebigger firestoputout.”).
It’sthesamereasonpromisingmoleculesget shelved.Notbecausetheylackpotential,but becausetheyfailtosolvethe urgent, budgeted problem thatdecision-makersneedsolved right now
Initially,Iwasirritated.Notbecauseanyone owedmea“yes,”butbecausemyconfidence intheideahadbeensohigh.
Butwhentheoutcomedidn’tmatchthe expectation,Ifacedachoice:
1.Keeppushingthesameoffertothesame peopleandhopepersistencewouldwork.
2.Stepback,re-examine,andpivot.
Ichosethesecond.
Here’sthethinkingprocess:
· Wastheaudienceright?Technicallyyes— theyfittheprofile.Buttheyweren'tinan activebuyingstateforthisoffer.
· Wastheofferclear?Notinthewaythat sparksimmediatecommitment.
· Wasthereskininthegame?No.Andthat wasthebiggestgap.
Insteadofofferingtheresourceforfree,I reframeditasapremium,focused engagement.
pricetagthatsignaledvalueandrequired commitment.
Ididn’tjustinvitepeopleto“come experience”something.
partnershipwithme—inanenvironmentthat removeddistractionsandacceleratedprogress.
Thepositioningchangedeverything.
Withinweeks,peoplewhohadpolitely passedonthefreeofferwerepayingforthe structuredone.
Inbiotechandpharma,“free”rarelydrivesactionatthe executiveorstrategiclevel.
requiresinvestment.
Whencompaniesandindividualspay,theyfocus.Theyallocate resources.Theypreparetocapturethevalue.
Therepackagedofferworkedbecauseit:
· specificproblem Defineda (businessownersstuckin operationalgrind).
· clearsolution Offereda (twodaysofstructuredstrategywith measurableoutcomes).
· Requiredemotionalandfinancialcommitment(theactof payingmadethemprioritize).
· Targetedtherightaudienceattherightstage(leaders activelyseekingbreakthrough,notpassiveobservers).
Whetheryou’repushingapersonalofferorlaunchinga multimillion-dollartherapy,theprincipleisidentical:
Ifthemarketdoesn’tengage,don’tdoubledownonthe originalformoftheidea.
Instead:
1.Audittheaudiencefit.Didyoutargetpeoplewiththe immediateproblemyousolve?
2.Examinetheofferclarity.Couldtheyinstantlyconnectyour solutiontotheirpainpoint?
3.Checkthestakes.Wasthereenoughcost,risk,orurgencyto forceadecision?
Ifanyoneoftheseisweak,yourconversionswillbetoo.
Whenyouemotionallycommittoaspecificversionofsuccess, youstartignoringdatathatcontradictsit.
partnerships,andevenhiring.
Youinterpretlukewarminterestas“theyneedmoreconvincing” insteadof“thisisn’ttherightfitrightnow.”
becauseyou believe theywilleventually
Detachmentdoesn’tmeanapathy.It meansrefusingtoletonepossible outcomebetheonlyoneyou pursue.
Inpractice,itlookslikethis:
· Yourunthepilotcampaign.The uptakeislow
· Insteadofdefendingthepilot,you runastructuredpost-mortem.
· Youidentifymisalignmentpoints.
· Yourepackage,reframe,or reposition—andtestagain quickly.
Inbiotechterms:yourunthetrial, youanalyzetheendpoints,andif theefficacydataisweak,youadjust theformulationorindicationrather thanpushingthesamedoseina biggertrial.
WheneverItakesomethingtomarket—beitaservice,astrategy session,oramajorresearchcollaboration—Irunitthroughthisfilter:
Ifnoonesaysyes,isthisideastillworthpursuinginadifferent form?
Iftheanswerisno,IknowI'mtooattachedtothecurrentformandnot focusedenoughontheunderlyingvalue.
· Don’tconfuseinterestwithintent.Peoplecanloveyouridea withoutbuyingit.
· Addstakes.Timelimits,cost,orcompetitiveadvantagemake decisionshappen.
· Scaleyoursamplesize.Sevenconversationswon'tgiveyoumarket truth.
· Detachfromform,protectthecorevalue.Thebestoutcomes oftenappearinthesecondorthirditeration.
Intheend,thepivotdidn’tjust“save”myidea—itmadeitstronger, moretargeted,andmorevaluabletothepeoplewhoneededitmost.
Andinbiotechandpharma,that’sthegamewe’reallplaying:turning promisingconceptsintomarket-readysolutionsbylettingthedata,not ourego,guidetheway
Executive Chairman In Ionis Pharmaceuticals Inc
The Antisense Architect
Dr. Stanley T. Crooke's
Legacy in Biotechnology
Dr.StanleyT.Crooke’s(Executive Chairman,IonisPharmaceuticalsInc.) storyisoneofavisionarywhotransformed thelandscapeofbiotechnology.Hisjourneyfrom humblebeginningsinIndianapolistothepinnacleof scientificinnovationisatestamenttohisrelentless pursuitofknowledgeandhisdesiretomakeatangible differenceintheworld.
Crooke’sacademicpathbeganatButlerUniversity, wherehelaidthefoundationforhisfutureinscience. HisthirstforknowledgeledhimtoBaylorCollegeof Medicine,wherehenotonlypursuedpharmacystudies butalsodelvedintothecomplexitiesofpharmacology, earningacombinedMD-PhDdegree.Abriefforay intolawschooldidnotdeterhim;instead,itreinforced hiscommitmenttomedicine.
Crooke’sresearchinpharmacologyatBaylorwasa preludetohisimpactfulworkinoncologyatBristol Laboratories.Here,hedelvedintothefightagainst cancer,contributingtothedevelopmentofnovel therapies.HistenureatSmithKline,nowknownas GlaxoSmithKline,wasmarkedbyleadershipand innovation,settingnewstandardsinpharmaceutical researchanddevelopment.
Hisworkduringthisperiodsetthestageforhisfuture endeavors,culminatinginthefoundingofIonis PharmaceuticalsInc.in1989.AsCEO,hesteeredthe companythroughtheunchartedwatersofantisense technology,facingskepticismhead-onandemergingas aleaderinRNA-targetedtherapeutics.
ThechallengesCrookefacedweremanifold,from leadingthedevelopmentofgroundbreakingtreatments toexpandingthecompany’sreachintonewtherapeutic areas.Hisleadershipwascharacterizedbya commitmenttoinnovationandscientificrigor,which becamethebedrockofIonisPharmaceuticals.
Crooke’svisionextendedbeyondthelaboratory.He soughttoimprovethelivesofpatientsandtheir families,fosteringacultureofinnovationwithinIonis.
Hismissionwasclear:toharnessantisensetechnology tocombatvariousdiseases.Thisdedicationledtothe approvalofSpinraza,alife-changingtreatmentfor spinalmuscularatrophy(SMA),andearnedhimthe prestigiousBreakthroughPrize.
Beyondhisscientificachievements,Crooke’spersonal journeyisequallyinspiring.Growingupina challengingenvironment,hedevelopedastrongwork ethicandapassionforscience,thanksinparttohis mentor,HarrisBusch.Hiscommitmenttohelping othersculminatedintheestablishmentofthen-Lorem Foundation,whichprovidesexperimentaltreatments forpatientswithraremutations.
AchievementsandAccoladestoEmbrace
Dr.Crooke’spioneeringworkhasearnedhim numeroushonors,includingthePrixGalienRoy VagelosProBonoHumanumAward,theAmerican ChemicalSociety’sE.B.HershbergAwardfor ImportantDiscoveriesinMedicinallyActive Substances,andtheLifetimeAchievementAward presentedbytheOligonucleotideTherapeutics Society.HealsoreceivedtheScripLifetime AchievementAwardandthe2019MassryPrizeforhis significantcontributionstothefieldofRNA-targeted therapeutics
In2023,CrookeretiredfromIonistofocusonhis scientificinterestsandphilanthropicwork,leaving behindalegacythatwillcontinuetoinfluencethe biotechindustryforyearstocome.
TransitioningtotheroleofExecutiveChairmanin 2023,Crookecontinuestoinfluencethetrajectoryof IonisPharmaceuticals.Hisguidanceensuresthe companyremainsatthevanguardofbiotechnology, pushingtheboundariesofwhat’spossibleindrug discoveryanddevelopment.
Hisstoryisoneofovercomingadversity,embracing challenges,andmakingalastingimpactontheworld throughscienceandcompassion.Dr.StanleyT. Crooke’snamewillforeverbesynonymouswith innovation,care,andtherelentlesspursuitofa healthierfutureforall.
Let’snotsugarcoatit.
Mosthealthcarecontactcentersarebuiltonbroken assumptions.Theystilltreatpatientcommunicationlikeahelp deskinsteadofagrowthengine.Leadersinstallnewtechand thinkthey’ve“innovated.”Theyhaven’t.Patientsstillsuffer throughlongwaits,repeatedtransfers,androboticscripts. Behindthescenes,calldatadiesinsilos,AIbuzzwordsfly aroundlikeconfetti,andnobodytrackstheonemetricthat actuallymatters:trustbuiltperinteraction.
Here’sthetruthnovendorwilltellyou:
Ifyourcontactcenterisn’tdirectlymakingpatients’lives easierwithin30secondsorless,it’salreadycostingyou—in no-shows,badreviews,andlifetimevalueerosion.
Thegoodnews?Asmallbutgrowinggroupofhealthsystems areflippingthescript.They’retreatingthecontactcenternot asasupportfunction,butasthefrontlineofexperience, loyalty,andrevenue.Thisishowthey’redoingit.
ActI:HowthePatientJourneyBreaksat“Hello”
Let’sstartwheretheproblembegins:thefirstcall.
Amotherphonesintorescheduleherchild’sappointment. She’sdirectedto“Press1forbilling,2forappointments,3for testresults…”Youknowthedrill.Sevenminuteslater,she finallyreachessomeone—onlytobetoldshe’scalledthe wrongdepartment.“Letmetransferyou.”Shewaitsagain.
Atthispoint,she’snotthinkingaboutyourcarequalityor physiciancredentials.She’sthinking: “If it’s this hard to talk to someone, how hard will it be to get treatment when it matters?”
Thatmomentrightthere?That’swheretrustdies.
Thisisn’tabouttech.It’saboutexpectations.Yourpatientsuse appstopayforgroceries,bookflights,andtransfermoney— allinseconds.Whenyourcontactcenterexperiencelags behindtheirdailynorm,youlookarchaic.Andtheygo elsewhere.
ActII:Why“DigitalTransformation”OftenJustMeans MoreConfusion
In2024,57%ofhealthcareexecutivessaid“improving consumerexperience”isatoppriorityfordigitalinvestment. It'sanicesentiment.Buthere’swhatreallyhappens:
· TheydeployAIforcallroutingbutdon’tredesign thejourney
· Theyaddachatbotthatsimplyredirectsusersto thesamephoneline.
· Theymigratetocloud-basedsystemsbutforget integration.
Sonowtheyhavemoredashboards,morevendors,and morenoise—butthepatientstillhitsthesamewall.
Realtransformationdoesn’tbeginwithtools.Itbegins withpurpose What,exactly,doyouwantthepatientto feelanddoaftereveryinteraction?Ifyourteamcan’t answerthatinonesentence,allthecloudmigrationsin theworldwon’thelp.
ActIII:WhattheWinnersDoDifferently(The TampaPlaybook)
Nowlet’stalkaboutthefewwhogetitright.
TakeTampaGeneralHospital.TheirExperienceCenter didn’tjustconsolidatecalls—itconsolidated intent. Everyinteractionhadonemission:resolvefrictionfast.
Theydidn’tstopatcalls.Theystudiedevery touchpoint:appointmentscheduling,follow-ups, cancellations,reminders.Thentheybuiltprocesses aroundthosekeymoments.Result?
· 47%jumpinonlineappointments.
· 75%increaseinappointmentslotsmadeavailable.
· 20%dropinno-shows.
That’snot“digitization.”That’soperationsintelligence executedlikewarstrategy.
AnothersysteminWisconsinwentfurther.They tackledlongholdtimes,highcallabandonment,and poorself-service.InsteadoftinkeringwiththeIVR, they:
· Deployedanintelligentvoiceassistanttrainedon real patientqueries.
· IntegratedEHRssothebotcouldpullappointment andbillingdatainreal-time.
· Shifted20%oftotalinteractionstoself-service.
· Gotcallabandonmentsunder5%.
Now80%ofcallsgetansweredinunder30seconds. Patientsstay.Revenueflows.Thecontactcenter becomesaconversionengine,notacostcenter.
IV:TheRealLeversBehindThisShift(NotWhat YouThink)
Sowhat’sreallydrivingthistransformation?
It’snotAI.Notcloud.Notevenomnichannel.
Theleaderswinningthisgamehaveruthlesslyfocusedon fivekeylevers:
1. TimetoResolution:Everyextrasecondcostsyou goodwill.Best-in-classcentersresolve85%ofpatient queriesinundertwominutes.That’syourbenchmark.
2. IntelligentEscalation:Mostsystemspushproblems downtoTier1agents.Winnersescalatestrategically— lettingautomationhandleroutinetasksand empoweringtrainedagentstostepinwhereitmatters most.
3. ProactiveOutreach:Don’twaitforpatientstocall. Sendreminders.Pushfollow-ups.Offercheck-ins. Patientsfeelcaredfor before theythinktoask.
4. UnifiedDataAccess:Ifyouragentcan’tseethe patient’sbillinghistory,appointmentschedule,and communicationtrailinonescreen,you’refighting blind.
5. RealFeedbackLoops:UseAInotjustforroutingbut toextractsentimentfromcalls.Knowwhatfrustrates patients before itbecomesapattern.
Andyes,compliancematters.HIPAA.Datasecurity.But that’sthefloor,nottheceiling.Securitywithoutempathy stilldrivespeopleaway.
ActV:TheDeathofthe“CallCenter”—AndtheRise ofPatientOps
Thisisn’taboutfixingadepartment.It’saboutreinventing thewayyourorganizationcommunicates.
Theterm“contactcenter”willdie.Whatwe’rebuilding nowisPatientOps—thefull-stackoperatingsystemfor personalized,real-time,lifetimepatientsupport.
Thatmeans:
· Movingfromreactiveservicetoproactiveexperience design.
· Treatingeverytouchpointasabrandingmoment.
· Trainingagentsnotasscript-readersbutasexperience architects.
· Usingtechtocreatehumanbandwidth—notreplaceit.
Thecontactcenterisyournewfrontdoor. Ifit’scluttered,slow,andoutdated,your patientwillneverstepinside.
ActVI:IfYou’reSerious,Bringin Killers—NotConsultants
Thistransformationisn’taDIYproject. Justaspatientsseekspecialistsfor complexneeds,healthcaresystems shouldstoprelyingongeneralisttech teams.
Youwantpartnerswho:
· Buildblueprintsforjourneyredesign —notjustfeaturechecklists.
· Offermanagedservicesthatactually delivermeasurableoutcomes.
· Runtrainingworkshopsthatelevate everyagentintoaretentionasset.
· Aligntheirperformanceincentives withyourpatientsatisfaction metrics.
FirmslikeCDWdon’tjustsellsoftware. Theyorchestratestrategy Theyco-own results.That’sthekindofpartnershipyou needifyou’redoneplayingcatch-up.
FinalWords:TheRealStakesof Inaction
Stillthinkingof“upgrading”yourcontact centernextyear?Letmepaintthereal risk.
Everytimeapatienthearsabusytone,or getstransferredtothewrongdesk,or doesn’tgetafollow-up—they’re formingaquietopinion:
“This place doesn’t care about me.”
Thatthoughtdoesn’tgetloggedina CRM.Butitdrivestheirnextdecision. Andyournextrevenuereport.
Yourcontactcenterisnotasideproject. It’syourbrand’sheartbeat.Fixit—or flatline.
Onthesurface,JenniferKirk’scareerpath lookslikeaseriesofdisconnecteddots:a childhooddefinedbyaseriousmedical diagnosis,apragmaticpivotintothehigh-stakes worldofBigSixaccounting,atwo-decadeascent throughthefinanceranksofanoilgiant,andboard seatsatmassiveenergyandenvironmentalservices companies.It’saformidable,ifconventional, trajectory.Buttounderstandtherealstory,youhave tolookatthespacesinbetween,atthemomentsof quietreckoningandthedeeplypersonalmissions thathaveguidedher Youhavetounderstandthe storyofthe“throwaway”horses.
Today,JenniferKirkistheChiefExecutive OfficerofExubrionTherapeutics,aveterinary medtechcompanyonthecuspofrevolutionizing howwetreatosteoarthritisinourpets.Itisarole that,fiveyearsago,shecouldneverhaveimagined. Butitisalsotheroleshehasbeenpreparingforher entirelife.Herjourneyisatestamenttotheideathat ourtruecallingoftenfindsusnotthroughastraight line,butthroughaseriesofunexpecteddetours—a healthcrisis,afamilymove,achanceconversation onabusinesstrip.Itisthestoryofhowalifelong loveforanimalsandadeepsenseofpurposefinally convergedwithalifetimeofcorporatedisciplineto createsomethingtrulytransformative.
ThestorybeginsinCalifornia,whereJennifer wasbornandraised.Atthetenderageofone, shewasdiagnosedwithType1Diabetes.The prognosisatthetimewasgrim;doctorstold hermothershewouldlikelybeblindorin kidneyfailurebytheageof20.Buther parents,fromalower-middle-class background,weredeterminedtodefythose odds.Theyinstilledinherafiercesenseof disciplineandresponsibilityaroundherhealth andeducation.Byagesix,inanactof extraordinarychildhoodgrit,shewasgiving herselfherowninsulinshots.
Thisearlycrucibleforgedtheprecisionand resiliencethatwouldbecomethebedrockof hercareer.Herchildhooddreamwastomajor inlinguisticsandrunadogrescue,butthe practicalrealitiesofherconditionmadesolid healthinsuranceanon-negotiable.Shemadea pragmaticpivot,choosingEconomicswitha focusinaccounting.Thedecisionnotonly gaveherthestabilitysheneededbutalsoset heronapaththatwouldlead,decadeslater,to thehighestechelonsofcorporatefinance. Becomingthefirstpersoninherfamilyto graduatefromcollegewasnotjustamilestone; itwasthefoundationofeverythingtocome.
AfterastintataBigSixaccountingfirm, Jenniferspent22yearsatOccidental Petroleum(NYSE:OXY),risingthrougha seriesofdemandingfinancerolesthatincluded VPofFinance,ChiefAccountingOfficer,and ultimately,SeniorVicePresidentleadingthe integrationofa$57billionacquisition.The fast-paced,globalenergysectorwasapowerful trainingground,givingheropportunitiestolive inmultiplelocationsandtravelextensively
Duringthistime,shebroadenedher perspectivebyjoiningtheboardsofmajor publiccompanies.In2016,shewasappointed totheboardofRepublicServices(NYSE: RSG),aleaderinenvironmentalservices.In 2024,shejoinedtheboardofSempra(NYSE: SRE),aFortune500energycompany
Herreputationwascemented:arecognized financialexpertwithadeepunderstandingof riskmanagement,M&Astrategy,andcorporate governance.Shewasatitanoffinance,amaster ofaworldofnumbersandshareholdervalue. Butadifferentcallingwasbeginningtostir
In2021,amidsttheglobaldisruptionofthe pandemic,Jenniferfeltadeeppulltowardwork thatalignedmorepersonallywithhervalues. Thisledhertoaseniorfinanceroleat Medtronic,theglobalmedtechleaderthat,ina poeticconvergenceofherpersonaland professionallives,manufacturedthevery insulinpumpsheusedeveryday.Sherelocated herfamilyfromTexastoMinnesota,embracing anewchapter
Itwastherethatherlifelongloveforanimals foundaprofoundnewexpression.Seekinga groundingactivityfortheirthreedaughters, Jenniferandherhusband,Adam,tookthemtoa localhorseranch.Theymetawomannamed Bree,aguidinglightwhoshowedthemthe therapeuticpowerofhorses—especiallythe overlookedanddiscardedones.Jennifer witnessedfirsthandthecalmingeffectthese “throwaway”horseshadonhermiddle daughter,andeverythingshifted.“Oncewesaw it,”sherecalls,“weknewwehadtodo something—notjusttorescuethehorses,butto givethempurposeagainbyhelpingpeople heal.”ThiswasthesparkthatignitedHealing withHorseplay,arescuemissionthatbecamea deeplypersonalcallingforherentirefamily
Thefinal,unexpecteddotwasconnectedona Medtronicbusinesstrip.Jennifermetawoman namedLaurie,whowouldonceagainchange thecourseofhercareer Theyconnected instantly,andwhenJennifersharedthestory ofthehorserescue,itsparkedadeeper conversation—firstaboutjointhealthin animals,thenaboutanovelisotopecalled Tin-117m,andultimatelyabout ExubrionTherapeutics,acompanyLaurie hadinvestedin.
Oneconversationledtoanother. Laurieeventuallydecidedtoleadthe nextroundoffundingforExubrion, butwithacriticalcondition:Jennifer hadtoagreetoleadthecompany LauriesawinJenniferarare combinationofstrategicclarity, financialacumen,andadeep,personal passionforanimalsandmedtech.The boardandfoundingteamagreed.In Mayof2025,thefinancetitanwhohad startedoutdreamingofananimal rescueofficiallybecametheCEOofa veterinarymedtechcompany
Today,sheleadsasmallbutmighty teamunitedbyasingle,resonant mission:improvingthelivesofpets livingwithosteoarthritis.Every memberoftheteamisapetparent, bringingapersonalpassiontotheir work.Sheissurroundedbyauniquely qualifiedteam,includingEric,the CCOwith30yearsofexperience; Nigel,theCOOandoneofthe technology’soriginalinventors;Bob, theempatheticChiefVeterinary Officer;andTim,theseasoned productionmanager Atthetop,Laurie servesnotjustasboardchair,butasa trustedcoachandthoughtpartner.“It’s aloteasiertoleadwhenyoubelieveso deeplyintheproduct,”Jennifersays.
AtExubrion,Jenniferissteeringa revolutioninanimalhealth.The company’spioneeringtreatment, ™ SynovetinOA ,isnotapainkiller;itis atargetedradiotherapeuticthat addressestheunderlyinginflammation thatcausesarthritis.Withatotal addressablemarketofover$6billion annuallyforthe20milliondogs sufferingfromosteoarthritisinthe U.S.alone,thegrowthpotentialis enormous.Hergoalistomorethan doublesalesyear-over-yearforthe nextthreeyearsandexpandintothe equinemarket.
ButforJennifer,thelegacysheisbuildingisaboutmorethan marketshare.Itisaboutintegratingherlife’spassionsintoa single,cohesivepurpose.“Iwanttosetanexamplethatit’s possibletoloveyourworkandincorporateitnaturallyintoyour life,”shesays.Heradvicetoaspiringwomenleadersinbiotech isareflectionofherownjourney:“Leadwithbothheadand heart.Inbiotech,wedealwithdataandmolecules,but ultimatelywe’reworkingtoimprovelives.That’snotasoft skill—it’sastrategicasset.”
Ultimately,hergoalistobuildalegacyofcompassion, innovation,andintegration,provingthatitispossibletocreate meaningfulchangeatwork,athome,andinthecommunity
Thelittlegirlwholearnedresiliencefromachronicillness,the financeexecutivewhomasteredtheartofthedeal,andthe motherwhofoundpurposeinarescuedhorsehaveall convergedintooneremarkableleader,nowpoisedtobring healingtomillionsofourbestfriends.
SCAN & GET INSPIRED, STAY UPDATED WITH ALL THE BUSINESS WORLD BUZZ WITH GLOBAL HEALTH CARE MAGAZINE
www.globalhealthcaremagazine.com